These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

687 related articles for article (PubMed ID: 33016924)

  • 1. mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer.
    Cafri G; Gartner JJ; Zaks T; Hopson K; Levin N; Paria BC; Parkhurst MR; Yossef R; Lowery FJ; Jafferji MS; Prickett TD; Goff SL; McGowan CT; Seitter S; Shindorf ML; Parikh A; Chatani PD; Robbins PF; Rosenberg SA
    J Clin Invest; 2020 Nov; 130(11):5976-5988. PubMed ID: 33016924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
    Aldous AR; Dong JZ
    Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous CD4
    Veatch JR; Jesernig BL; Kargl J; Fitzgibbon M; Lee SM; Baik C; Martins R; Houghton AM; Riddell SR
    Cancer Immunol Res; 2019 Jun; 7(6):910-922. PubMed ID: 31043415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors.
    Lu YC; Zheng Z; Robbins PF; Tran E; Prickett TD; Gartner JJ; Li YF; Ray S; Franco Z; Bliskovsky V; Fitzgerald PC; Rosenberg SA
    Mol Ther; 2018 Feb; 26(2):379-389. PubMed ID: 29174843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D.
    Sim MJW; Lu J; Spencer M; Hopkins F; Tran E; Rosenberg SA; Long EO; Sun PD
    Proc Natl Acad Sci U S A; 2020 Jun; 117(23):12826-12835. PubMed ID: 32461371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model.
    Peterson M; Murphy SN; Lainson J; Zhang J; Shen L; Diehnelt CW; Johnston SA
    BMC Immunol; 2020 May; 21(1):25. PubMed ID: 32370785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice.
    Haabeth OAW; Blake TR; McKinlay CJ; Waymouth RM; Wender PA; Levy R
    Proc Natl Acad Sci U S A; 2018 Sep; 115(39):E9153-E9161. PubMed ID: 30201728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mRNA Cancer Vaccines.
    Fiedler K; Lazzaro S; Lutz J; Rauch S; Heidenreich R
    Recent Results Cancer Res; 2016; 209():61-85. PubMed ID: 28101688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mRNA therapeutics in cancer immunotherapy.
    Beck JD; Reidenbach D; Salomon N; Sahin U; Türeci Ö; Vormehr M; Kranz LM
    Mol Cancer; 2021 Apr; 20(1):69. PubMed ID: 33858437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.
    Carreno BM; Magrini V; Becker-Hapak M; Kaabinejadian S; Hundal J; Petti AA; Ly A; Lie WR; Hildebrand WH; Mardis ER; Linette GP
    Science; 2015 May; 348(6236):803-8. PubMed ID: 25837513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results.
    Rappaport AR; Kyi C; Lane M; Hart MG; Johnson ML; Henick BS; Liao CY; Mahipal A; Shergill A; Spira AI; Goldman JW; Scallan CD; Schenk D; Palmer CD; Davis MJ; Kounlavouth S; Kemp L; Yang A; Li YJ; Likes M; Shen A; Boucher GR; Egorova M; Veres RL; Espinosa JA; Jaroslavsky JR; Kraemer Tardif LD; Acrebuche L; Puccia C; Sousa L; Zhou R; Bae K; Hecht JR; Carbone DP; Johnson B; Allen A; Ferguson AR; Jooss K
    Nat Med; 2024 Apr; 30(4):1013-1022. PubMed ID: 38538867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation-Derived Neoantigens for Cancer Immunotherapy.
    Castle JC; Uduman M; Pabla S; Stein RB; Buell JS
    Front Immunol; 2019; 10():1856. PubMed ID: 31440245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges and advances towards the rational design of mRNA vaccines.
    Pollard C; De Koker S; Saelens X; Vanham G; Grooten J
    Trends Mol Med; 2013 Dec; 19(12):705-13. PubMed ID: 24138818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer Neoantigens.
    Schumacher TN; Scheper W; Kvistborg P
    Annu Rev Immunol; 2019 Apr; 37():173-200. PubMed ID: 30550719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved.
    Fritsch EF; Burkhardt UE; Hacohen N; Wu CJ
    Cancer Immunol Res; 2020 Dec; 8(12):1465-1469. PubMed ID: 33262163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An immunogenic personal neoantigen vaccine for patients with melanoma.
    Ott PA; Hu Z; Keskin DB; Shukla SA; Sun J; Bozym DJ; Zhang W; Luoma A; Giobbie-Hurder A; Peter L; Chen C; Olive O; Carter TA; Li S; Lieb DJ; Eisenhaure T; Gjini E; Stevens J; Lane WJ; Javeri I; Nellaiappan K; Salazar AM; Daley H; Seaman M; Buchbinder EI; Yoon CH; Harden M; Lennon N; Gabriel S; Rodig SJ; Barouch DH; Aster JC; Getz G; Wucherpfennig K; Neuberg D; Ritz J; Lander ES; Fritsch EF; Hacohen N; Wu CJ
    Nature; 2017 Jul; 547(7662):217-221. PubMed ID: 28678778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines.
    Roesler AS; Anderson KS
    Methods Mol Biol; 2022; 2410():649-670. PubMed ID: 34914074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoantigen vaccine: an emerging tumor immunotherapy.
    Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z
    Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.